靶向前列腺酸性磷酸酶的[68Ga]Ga-OncoACP3-DOTA首次人体PET研究
在25例前列腺癌患者中配对比较[68Ga]Ga-OncoACP3-DOTA与[18F]PSMA-1007 PET显像,前者唾液腺和肾脏本底摄取显著更低(p<0.002),局部或转移灶SUVmax总体无显著差异;11/25对显像中OncoACP3表现更优,8/25对中PSMA-1007更优;OncoACP3改变了部分生化复发和已知转移患者的治疗管理。
要点
- OncoACP3在唾液腺和肾脏的本底摄取显著低于PSMA-1007(p<0.002)。
- 局部或转移性前列腺癌中两种示踪剂SUVmax总体无显著差异。
- OncoACP3在11/25对显像中表现更优,改变了部分患者治疗管理。
核心结论
- OncoACP3-DOTA具有强烈且可靠的肿瘤摄取及低脱靶活性,支持未来开展PET显像及β和α粒子放射性配体治疗试验。
研究设计与样本
- 首次人体研究,在25例前列腺癌患者中分析并配对[68Ga]Ga-OncoACP3-DOTA与[18F]PSMA-1007 PET扫描。
- 采用Wilcoxon秩和检验比较两种示踪剂的生物分布和肿瘤摄取。
主要发现
- OncoACP3在唾液腺和肾脏的本底摄取低,与PSMA-1007在这些器官的高摄取有显著差异(p<0.002)。
- 局部或转移性前列腺癌中两种示踪剂的SUVmax无显著差异。
- 在11/25对配对扫描中OncoACP3表现更优,在8/25对中PSMA-1007表现更优。
- OncoACP3改变了3/6例生化复发患者和2/12例已知转移患者的治疗管理。
关键数值与推荐
- 优势定义为检出病灶数多>10%或病灶SUVmax高>50%。
临床怎么用
- OncoACP3 PET可用于前列腺癌显像,尤其关注低脱靶摄取场景,并可能影响生化复发或转移患者的治疗决策。
局限性
- 回顾性比较可能存在偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prostate-specific membrane antigen (PSMA)-targeted theranostic agents have transformed prostate cancer (PC) management, but their performance is limited by variable PSMA expression and off-target uptake. We investigates the first-in-human positron emission tomography (PET) imaging of prostatic acid phosphatase (ACP3), a novel and highly specific PC target, using the radioligand [68Ga]Ga-OncoACP3-DOTA. We analyzed and matched [68Ga]Ga-OncoACP3-DOTA and [18F]PSMA-1007 PET scans in a cohort of 25 patients with PC. We compared the biodistribution and tumor uptake of the two tracers using the Wilcoxon rank-sum test and compared their performance. Superiority was defined as >10% more lesions detected or >50% higher lesional maximum standardized uptake value (SUVmax). [68Ga]Ga-OncoACP3-DOTA showed low background uptake, including in the salivary glands and kidneys, with a significant difference from the high [18F]PSMA-1007 uptake in these organs (p < 0.002). Overall, SUVmax in localized or metastatic PC did not significantly differ between the two tracers. Better [68Ga]Ga-OncoACP3-DOTA performance was observed in 11/25 matched scan pairs, and better [18F]PSMA-1007 performance in eight of 25 pairs. [68Ga]Ga-OncoACP3-DOTA changed therapeutic management in three of six patients with biochemical recurrence, and in two of 12 patients with known metastases. Although the retrospective comparison is potentially biased, the intense and reliable tumor uptake and the low off-target activity of OncoACP3-DOTA provide a strong rationale for future exploration in trials on PET imaging and radioligand therapy with β- and α-particle emitters.
引用
- Backhaus P, Cazzamalli S, Oehler S, et al. Translational and First-in-Human Positron Emission Tomography Targeting Prostatic Acid Phosphatase in Prostate Cancer Using the Ligand [68Ga]Ga-OncoACP3-DOTA. Eur Urol. 2025. PMID: 41412909. doi:10.1016/j.eururo.2025.11.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。